Latigo Biotherapeutics, Inc. LTGO
At closeNov 5, 2026, 4:06 PM EST
After hours · Nov 5, 4:06 PM ET
- YTD
- -28.71%
- 1 year
- -28.71%
- Market cap
- 862.55M
- EPS (ttm)
- -2.34
- Shares out
- 66.30M
- Forward P/E
- -7.44
- YTD return
- -28.71%
- 1-year return
- -28.71%
- Volume
- 424.28K
- Avg volume
- 333.13K
- Open
- 13.21
- Previous close
- 14.04
- Day's range
- 10.45 – 13.23
- 52-week range
- 13.01 – 25.00
- Analysts
- Strong Buy
- Price target
- 52.25 (+301.6%)
5D -2.38 (-15.46%)
Key statistics
- Enterprise value
- 1.31B
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- 0
- Total cash
- 55.00M
- Total debt
- 31.25M
- Return on equity
- 0.00%
- Short % of float
- 0.00%
- 50-day average
- 19.18
- 200-day average
- 19.18
Analyst view
Consensus: strong buy
- Target (low)
- 36.00
- Target (mean)
- 52.25
- Target (high)
- 73.00
- Strong buy0
- Buy4
- Hold0
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate 0.00.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Sep 3, 2026 | Jun 30, 2026 | -0.61667 | -27.59 | -26.97 | -4,374.03% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Sep 1, 2026 | Leerink Partners | init | — | Outperform |
| Sep 1, 2026 | Jefferies | init | — | Buy |
| Sep 1, 2026 | Guggenheim | init | — | Buy |
About Latigo Biotherapeutics, Inc.
Latigo Biotherapeutics, Inc. develops non-opioid pain medicines designed to stop the transmission of pain without the risk of addiction. The company's pipeline includes LTG-001, an oral NaV1.8 inhibitor designed to provide fast-acting, opioid-sparing relief for the treatment of acute pain; LTG-321, a NaV1.8 inhibitor candidate developed for the treatment of chronic musculoskeletal pain, starting with osteoarthritis; and LTG-418, a NaV1.8 inhibitor developed for the treatment of acute and chronic pain. Latigo Biotherapeutics, Inc. was formerly known as WVB-Desmond, Inc. and changed its name to Latigo Biotherapeutics, Inc. in March 2019. Latigo Biotherapeutics, Inc. was incorporated in 2018 and is based in Thousand Oaks, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- latigobio.com
News
Latigo Biotherapeutics Q3 EPS $(0.55) Beats $(0.58) Estimate 
Latigo Biotherapeutics Reports Third Quarter 2026 Financial Results and Recent Business Highlights 
Latigo Biotherapeutics Announces CEO Transition to Support the Company's Next Phase of Growth 
Latigo Biotherapeutics to Participate in Upcoming Investor Conferences in November 
Vertex Built The NaV1.8 Market, Latigo May Be The One To Profit From It 
Latigo Biotherapeutics (NASDAQ:LTGO) Hits New 12-Month Low – Here’s Why 
Latigo Biotherapeutics, Inc.’s Quiet Period Will End on September 16th (NASDAQ:LTGO) 
Latigo Biotherapeutics Q2 EPS $(27.59) Up From $(36.52) YoY, Sales $0.00, Same YoY 
Latigo Biotherapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights 
Leerink Partners Initiates Coverage On Latigo Biotherapeutics with Outperform Rating, Announces Price Target of $36
Your note
Sign in to keep a note on LTGO — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| 5AM VENTURES VI, L.P. | Beneficial Owner of more than 10% of a Class of Security | Conversion of Exercise of derivative security | Aug 9, 2026 | 0 |
| FORESITE CAPITAL MANAGEMENT V, LLC. | Beneficial Owner of more than 10% of a Class of Security | Purchase | Aug 9, 2026 | 0 |
| SANOFI SA | Beneficial Owner of more than 10% of a Class of Security | Conversion of Exercise of derivative security | Aug 9, 2026 | 0 |
| SEIDENBERG BETH C | Director and Beneficial Owner of more than 10% of a Class of Security | Conversion of Exercise of derivative security | Aug 9, 2026 | 0 |
| TANANBAUM JAMES B | Director and Beneficial Owner of more than 10% of a Class of Security | Purchase | Aug 9, 2026 | 0 |
| WESTLAKE BIOPARTNERS FUND I, L.P. | Beneficial Owner of more than 10% of a Class of Security | Conversion of Exercise of derivative security | Aug 9, 2026 | 0 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity Contrafund | 1.42% | 940,228 | 14.61M | Aug 30, 2026 |
| Fidelity Select Portfolios-Select Biotechnology Portfolio | 0.72% | 480,316 | 7.46M | Aug 30, 2026 |
| Fidelity Select Portfolios-Select Health Care Portfolio | 0.32% | 212,500 | 3.30M | Aug 30, 2026 |
| Fidelity Contrafund-Fidelity Contrafund K6 | 0.30% | 199,400 | 3.10M | Aug 30, 2026 |
| Fidelity Advisor Series VII-Fidelity Advisor Biotechnology Fund | 0.29% | 191,400 | 2.97M | Aug 30, 2026 |
| Fidelity Advisor Series VII-Fidelity Advisor Health Care Fund | 0.16% | 105,200 | 1.63M | Aug 30, 2026 |